NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00781-3492-12 | 00781-3492 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Mar 26, 2020 | Aug 31, 2024 | No Longer Used | |
00781-3079-12 | 00781-3079 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | May 29, 2019 | Sep 30, 2024 | No Longer Used | |
62332-0650-10 | 62332-0650 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Dec 22, 2022 | In Use | ||
70700-0284-98 | 70700-0284 | fulvestrant | FULVESTRANT | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Aug 19, 2021 | In Use | ||
00310-0720-10 | 00310-0720 | Fulvestrant | Faslodex | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Nov 1, 2010 | In Use | ||
67457-0311-05 | 67457-0311 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Sep 9, 2019 | In Use | ||
16714-0070-02 | 16714-0070 | fulvestrant | FULVESTRANT | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Aug 23, 2021 | In Use | ||
70771-1626-08 | 70771-1626 | Fulvestrant | FULVESTRANT | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Dec 14, 2021 | In Use | ||
25021-0471-74 | 25021-0471 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Sep 15, 2024 | In Use | ||
70710-1688-08 | 70710-1688 | fulvestrant | FULVESTRANT | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Dec 14, 2021 | In Use | ||
68001-0424-85 | 68001-0424 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Dec 10, 2019 | Jul 31, 2022 | In Use | |
83634-0203-74 | 83634-0203 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Feb 28, 2024 | In Use | ||
68001-0522-85 | 68001-0522 | Fulvestrant | FULVESTRANT | 250.0 mg/5mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Oct 29, 2021 | In Use | ||
68842-0301-12 | 68842-0301 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | May 29, 2019 | In Use | ||
68001-0484-85 | 68001-0484 | Fulvestrant | Fulvestrant | 250.0 mg/5mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Mar 1, 2021 | In Use | ||
16729-0436-30 | 16729-0436 | Fulvestrant | FULVESTRANT | 250.0 mg/5mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Jan 21, 2021 | In Use | ||
00781-3532-12 | 00781-3532 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Nov 1, 2023 | In Use | ||
71288-0555-86 | 71288-0555 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Nov 21, 2019 | Jan 31, 2027 | In Use | |
16714-0118-02 | 16714-0118 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Feb 26, 2020 | May 22, 2022 | No Longer Used | |
63020-0210-21 | 63020-0210 | Fruquintinib | Fruzaqla | 1.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Nov 8, 2023 | In Use | |
63020-0225-21 | 63020-0225 | Fruquintinib | Fruzaqla | 5.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Nov 8, 2023 | In Use | |
69639-0106-01 | 69639-0106 | Fosnetupitant and Palonosetron | AKYNZEO | 260.0 mg/20mL, 0.28 mg/20mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist, Substance P/Neurokinin 1 | Intravenous | Aug 1, 2023 | In Use | |
69639-0102-01 | 69639-0102 | Fosnetupitant and Palonosetron | AKYNZEO | 260.0 mg/1, 0.28 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Intravenous | Apr 20, 2018 | In Use | |
69639-0105-01 | 69639-0105 | Fosnetupitant and Palonosetron | AKYNZEO | 260.0 mg/20mL, 0.28 mg/20mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Intravenous | Jun 15, 2020 | In Use | |
16729-0240-03 | 16729-0240 | FOSAPREPITANT | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Oct 22, 2020 | In Use |
Found 11465 results — Export these results